Market cap
$16,614 Mln
Revenue (TTM)
$1,054 Mln
P/E Ratio
19.4
P/B Ratio
10.1
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 37.60 | 118.23 | 114.85 | 106.83 | 190.92 |
| EBIT | 227.10 | 3,289.10 | 136.39 | 28.59 | 16.39 |
| Net Profit | -67.11 | 641.49 | 378.76 | 48.00 | 29.56 |
| EPS | -68.94 | 606.55 | 353.27 | 45.08 | 27.26 |
| Book Value | -- | -- | -- | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-25 | Dec-24 |
| EBIT-Margin
| -88.07 | -1,243.70 | 5.73 | -18.33 | -84.63 |
| Net Margin
| -- | -- | 71.69 | -- | -- |
| Return on equity
| -118.16 | -100.14 | -- | 163.18 | 300.78 |
| Return on Capital
| -50.41 | -49.64 | -- | -30.01 | -56.08 |
| Return on Assets
| -35.21 | -39.29 | 26.53 | -17.65 | -37.71 |
| Debt to Equity (x)
| -- | -- | 0.00 | -5.35 | -8.10 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Ascendis Pharma A/S - ADR
|
--
|
-30.01
|
-56.08
|
-65.14
|
-59.07
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
--
--
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Ascendis Pharma A/S - ADR
|
--
|
163.18
|
300.78
|
-818.43
|
-101.69
|
|
Peer Median
|
-40.29
|
--
|
--
|
--
|
--
|
ROA
26.53
Higher than Peers by 57.37
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Ascendis Pharma A/S - ADR
|
26.53
|
-17.65
|
-37.71
|
-50.27
|
-53.64
|
|
Peer Median
|
-30.84
|
--
|
--
|
--
|
--
|
EBIT Margin
5.73
Higher than Peers by 87.94
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Ascendis Pharma A/S - ADR
|
5.73
|
-18.33
|
-84.63
|
-161.25
|
-1,068.30
|
|
Peer Median
|
-82.21
|
--
|
--
|
--
|
--
|
Net Margin
71.69
Higher than Peers by 161.57
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Ascendis Pharma A/S - ADR
|
71.69
|
-31.67
|
-103.97
|
-180.51
|
-1,139.63
|
|
Peer Median
|
-89.88
|
--
|
--
|
--
|
--
|
Cash Profit Margin
0.00
Higher than Peers by 0.00
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Ascendis Pharma A/S - ADR
|
0.00
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.00
|
--
|
--
|
--
|
--
|
Revenue Growth
114.85
Higher than Peers by 60.82
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Ascendis Pharma A/S - ADR
|
114.85
|
0.90
|
0.36
|
4.21
|
5.58
|
|
Peer Median
|
54.03
|
--
|
--
|
--
|
--
|
EBIT Growth
136.39
Higher than Peers by 137.34
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Ascendis Pharma A/S - ADR
|
136.39
|
58.80
|
28.45
|
21.33
|
-43.85
|
|
Peer Median
|
-0.95
|
--
|
--
|
--
|
--
|
Net Profit Growth
378.76
Higher than Peers by 385.94
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Ascendis Pharma A/S - ADR
|
378.76
|
42.07
|
21.47
|
17.45
|
-52.04
|
|
Peer Median
|
-7.19
|
--
|
--
|
--
|
--
|
EPS Growth
353.27
Higher than Peers by 338.83
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Ascendis Pharma A/S - ADR
|
353.27
|
0.44
|
0.26
|
0.18
|
-0.46
|
|
Peer Median
|
14.43
|
--
|
--
|
--
|
--
|
Book Value Growth
816.12
Higher than Peers by 826.58
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Ascendis Pharma A/S - ADR
|
816.12
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-10.46
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Ascendis Pharma A/S - ADR
|
--
|
-5.35
|
-8.10
|
-5.10
|
2.35
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.05
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Ascendis Pharma A/S - ADR
|
0.05
|
-2.99
|
-4.65
|
-2.99
|
1.62
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
2.99
Lower than Peers by 2.81
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Ascendis Pharma A/S - ADR
|
2.99
|
1.04
|
1.17
|
0.95
|
1.29
|
|
Peer Median
|
5.80
|
--
|
--
|
--
|
--
|
Quick Ratio
2.32
Lower than Peers by 3.37
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Ascendis Pharma A/S - ADR
|
2.32
|
0.76
|
0.84
|
0.67
|
1.11
|
|
Peer Median
|
5.69
|
--
|
--
|
--
|
--
|
Interest Coverage
1.62
Higher than Peers by 3.71
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Ascendis Pharma A/S - ADR
|
1.62
|
-1.64
|
-4.70
|
-9.76
|
-17.82
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
21.25
Higher than Peers by 2.27
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Ascendis Pharma A/S - ADR
|
21.25
|
22.79
|
45.73
|
13.45
|
23.27
|
|
Peer Median
|
18.97
|
--
|
--
|
--
|
--
|
Asset Turnover
0.37
Higher than Peers by 0.30
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Ascendis Pharma A/S - ADR
|
0.37
|
0.56
|
0.36
|
0.28
|
0.05
|
|
Peer Median
|
0.07
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Ascendis Pharma A/S - ADR
|
--
|
85.52
|
101.52
|
32.72
|
50.35
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Ascendis Pharma A/S - ADR
|
--
|
1,056.70
|
2,081.92
|
1,397.01
|
3,100.85
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Ascendis Pharma A/S - ADR
|
--
|
331.01
|
787.97
|
804.62
|
2,414.27
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Ascendis Pharma A/S - ADR
|
--
|
811.21
|
1,395.47
|
625.11
|
736.93
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|